Professor of Medicine / University of Massachusetts Medical School
Rheumatology
Dr. Jonathan Kay, MD
|
|
Give Review
Jonathan is an expert in the field of Rheumatology. He researched medicine at University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is a top medical university. University of California San Francisco School of Medicine has a rank of 3 in research and a 3 in primary care He over the years received 11 awards: "Meaningful Use Stage 1 Certification", "Charles Burnett Special Recognition Award", "Fellow (FACP)", "Fellow (FACR)", "Postdoctoral Fellowship", "Honor Student in Medicine", "Presidents Undergraduate Fellowship", "Summer Fellowship", "Scholarship", "Top MD" and "Super Doctor". Dr. Jonathan Kay is also published. He has 62 publications published. The lastest publication: "Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.' Jonathan Kay accepts Medicare.
Publications
- Brief Report: Development and Validation of a Semiautomated Method to Measure Erosion Volume in Inflammatory Arthritis by Computed Tomography Scanning.
- Tocilizumab in early progressive rheumatoid Arthritis: FUNCTION, a randomised controlled trial.
- Biosimilars in rheumatology: current perspectives and lessons learnt.
- Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid Arthritis who discontinued prior anti-tumour necrosis factor therapy: post...
- Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammation.
- Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study.
- Current status of nephrogenic systemic fibrosis.
- Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients w...
- Biosimilars to treat inflammatory Arthritis: the challenge of proving identity.
- The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or Ankylosing spondylitis.
- Fibrosis-Associated Single-Nucleotide Polymorphisms in TGFB1 and CAV1 Are Not Associated With the Development of Nephrogenic Systemic Fibrosis.
- Relapsing polychondritis.
- Validation of a screening instrument for nephrogenic systemic fibrosis.
- Rheumatoid Arthritis: Erosion defined: back to basics.
- The advent of biosimilar therapies in rheumatology-"O Brave New World".
- Golimumab in patients with active rheumatoid Arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the ran...
- Assessment of control of rheumatoid Arthritis disease activity.
- Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations.
- Biosimilars: a regulatory perspective from America.
- Erratum to: Treating rheumatoid Arthritis to target: an international initiative.
- Treating rheumatoid Arthritis to target: an international initiative.
- Sensorineural Hearing Loss following Imatinib (Gleevec) Administration.
- Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
- Diabetes mellitus and insulin resistance in patients with rheumatoid Arthritis: Risk reduction in a chronic inflammatory disease.
- Quantitative assessment of dermal Cellularity in nephrogenic systemic fibrosis: a diagnostic aid.
- Rheumatic manifestations of diabetes mellitus.
- Gadolinium and systemic fibrosis: guilt by association.
- 2010 Rheumatoid Arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
- The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid Arthritis: Phase 2 methodological report.
- The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid Arthritis: methodological report phase I.
- 2010 rheumatoid Arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
- Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, Ankylosing spondylitis, and psoriatic arthritis.
- Bone damage in rheumatoid Arthritis: mechanistic insights and approaches to prevention.
- Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid Arthritis receiving concurrent glucocorticoids or bisphosphonates.
- Treating rheumatoid Arthritis to target: recommendations of an international task force.
- Nephrogenic systemic fibrosis: a pathologic study of autopsy cases.
- Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole ...
- Case records of the Massachusetts General Hospital. Case 37-2009. A 46-year-old woman with Chronic renal failure, leg swelling, and skin changes.
- Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
- Golimumab in patients with active rheumatoid Arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double...
- E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with activ...
- Methotrexate: the gold standard without standardisation.
- Physician ability to assess rheumatoid Arthritis disease activity using an electronic medical record-based disease activity calculator.
- A rheumatology-specific informatics-based application with a Disease activity calculator.
- Nephrogenic systemic fibrosis: a new concern for rheumatologists.
- Imatinib mesylate treatment of nephrogenic systemic fibrosis.
- Non-crystalline and crystalline rheumatic disorders in chronic kidney Disease.
- Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity.
- Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid Arthritis: a twelve-month, multicenter, randomized, double-bli...
- Golimumab in patients with active rheumatoid Arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.
- Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen.
- Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin.
- Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure.
- Case records of the Massachusetts General Hospital. Case 39-2006. A 24-year-old woman with systemic Lupus erythematosus, seizures, and right arm weakness.
- Wegener's granulomatosis: is biologic therapy useful?
- Case records of the Massachusetts General Hospital. Case 4-2006. A 79-year-old woman with myalgias, fatigue, and shortness of breath.
- Case records of the Massachusetts General Hospital. Case 31-2005. A 60-year-old man with skin lesions and renal insufficiency.
- Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal Disease and thickening o...
- Advanced glycation endproducts and osteoArthritis.
- Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cry...
- Biosimilars in rheumatology: what the clinician should know.
Schools
University Of California San Francisco School Of Medicine
Hospital Of The University Of Pennsylvania
Brigham WomensHarvard
Procedures Preformed
- Joint Drainage
- Myofascial Trigger Point Injection
- Steroid Injection
- Trigger Point Injection
- View All
Conditions Treated
- Achilles Tendinitis
- Adhesive Capsulitis
- Ankylosing Spondylitis
- Arthritis
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
- Charles Burnett Special Recognition Award
- Fellow (FACP)
- Fellow (FACR)
- Postdoctoral Fellowship
- Honor Student in Medicine
- President’s Undergraduate Fellowship
- Summer Fellowship
- Scholarship
- Top MD
- Super Doctor
Education
-
Brigham and Women's Hospital -
University of Pennsylvania Health System -
University of California San Francisco School of Medicine -
Harvard College
Hospital
-
UMass Memorial Medical Center
Drug Facts
| NPI NUMBER | 1699766964 | |
| NPPES Provider LastName | KAY | |
| NPPES Provider FirstName | JONATHAN | |
| NPPES Provider ZIPCode | 016550002 | |
| NPPES Provider State | MA | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 607.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 19.0 | |
| Percent Opioid Claims | 3.13 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1699766964 |
| Last Name Of The Provider | KAY |
| First Name Of The Provider | JONATHAN |
| View All |
Similar Doctors
|
|
Dr. Rajandeep S. Paik, MD |
|
|
Dr. Youmna Lahoud, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James P. Figueroa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ellen M. Gravallese, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Beata J. Cieslak-Skowronska, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen I. Salomon-Escoto, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evelyn S. Love, MD
This Doctor is OpenDoctor Recommended.
|